Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 5

1.

Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24.

Chiriva-Internati M, Liu Y, Weidanz JA, Grizzi F, You H, Zhou W, Bumm K, Barlogie B, Mehta JL, Hermonat PL.

Blood. 2003 Nov 1;102(9):3100-7. Epub 2003 Jul 10.

2.

Alternative pathways of cell death to circumvent pleiotropic resistance in myeloma cells: role of cytotoxic T-lymphocytes.

Shtil AA, Turner JG, Dalton WS, Yu H.

Leuk Lymphoma. 2000 Jun;38(1-2):59-70. Review.

PMID:
10811448
3.

T cell-based targeted immunotherapies for patients with multiple myeloma.

Wang L, Jin N, Schmitt A, Greiner J, Malcherek G, Hundemer M, Mani J, Hose D, Raab MS, Ho AD, Chen BA, Goldschmidt H, Schmitt M.

Int J Cancer. 2015 Apr 15;136(8):1751-68. doi: 10.1002/ijc.29190. Epub 2014 Sep 19. Review.

4.

Targeted therapy for HM1.24 (CD317) on multiple myeloma cells.

Harada T, Ozaki S.

Biomed Res Int. 2014;2014:965384. doi: 10.1155/2014/965384. Epub 2014 Jul 17. Review.

5.

Tumour-associated antigens in multiple myeloma.

Pellat-Deceunynck C.

Br J Haematol. 2003 Jan;120(1):3-9. Review. No abstract available.

PMID:
12492570

Supplemental Content

Support Center